<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03995563</url>
  </required_header>
  <id_info>
    <org_study_id>2019-04-011</org_study_id>
    <nct_id>NCT03995563</nct_id>
  </id_info>
  <brief_title>The Effect of Epidural Steroid Use in Patients With Continous Epidural Block in PHN Patients.</brief_title>
  <official_title>The Effect of Epidural Steroid Use on Pain Relief in Patients With Continuous Epidural Nerve Block in Postherpetic Neuralgia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficiency of epidural steroid injection in patients who has postherpetic neuralgia is
      well known. In this study, the purpose is whether the continous epidural steroid injection is
      effective or not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continous epidural injection will be done during 10 days. D group will be injected a 0.19%
      ropivacaine 8mL and dexametasone 1mg every other day during 10 days.

      Continous epidural injection will be done during 10 days N group will be injected a 0.19%
      ropivacaine 8mL only every other day during 10 days
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS score</measure>
    <time_frame>up to 10 days</time_frame>
    <description>The investigator set the primary outcome If there is a 50% reduction of VAS score.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neuralgia,Postherpetic</condition>
  <arm_group>
    <arm_group_label>D group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.19% Ropivacaine 8mL + Dexametasone 1mg every other day injection during 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.19% Ropivacaine 8mL only every other day injection during 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.
.</description>
    <arm_group_label>D group</arm_group_label>
    <other_name>DEXA-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days</description>
    <arm_group_label>D group</arm_group_label>
    <arm_group_label>N group</arm_group_label>
    <other_name>Rocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who has herpes zoster

          -  Patients has a period (at least 1month) after onset of herpes zoster

          -  Patients has a definite symptom along dermatome

          -  ASA class I - II

          -  Age : 18 - 80 years

        Exclusion Criteria:

          -  Patients who has a cancer

          -  Patients who has a neurologic, psychologic, renal, hepatic and hematologic disease

          -  Patients who has a other dermatologic disease

          -  Patients who has major operation &amp; procedure history

          -  Patients who has a other pain origin

          -  Patients who can not be inserted epidural catheter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jung Eun Kim, MD, PhD</last_name>
    <phone>+82-10-7271-5391</phone>
    <email>geri200@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kangnam sacred heart hospital</name>
      <address>
        <city>Seoul</city>
        <state>Yeongdeungpo-gu</state>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Eun Kim, MD, PhD</last_name>
      <phone>+82-10-7271-5391</phone>
      <email>geri200@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Jung Eun Kim</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD sharing is not decided.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

